SCHEMBL436157

SCHEMBL436157

C/C=C(O)/C=C(O)/C=C/CCCCCCCCCCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.47
PPARA Q07869 5/20 0.47
TSHR P16473 1/20 0.46
PTPN1 P18031 4/20 0.46
TERT O14746 3/20 0.46
PPARD Q03181 3/20 0.46
TOP1 P11387 3/20 0.46
MAPT P10636 2/20 0.46
BLM P54132 2/20 0.46
HSD17B10 Q99714 2/20 0.46
FABP4 P15090 2/20 0.46
GMNN O75496 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
APEX1 P27695 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436158 1.00 PPARG (0.47) PPARGPPARATSHRPTPN1TERT
SCHEMBL4751614 0.82 PTPN1 (0.56) PPARGPPARAPTPN1TERTPPARD
SCHEMBL3345156 0.82 PTPN1 (0.56) PPARGPPARAPTPN1TERTPPARD
SCHEMBL8083753 0.82 PTPN1 (0.56) PPARGPPARAPTPN1TERTPPARD
SCHEMBL3345152 0.82 PTPN1 (0.56) PPARGPPARAPTPN1TERTPPARD
SCHEMBL5498294 0.82 PTPN1 (0.56) PPARGPPARAPTPN1TERTPPARD
SCHEMBL4751612 0.82 PTPN1 (0.56) PPARGPPARAPTPN1TERTPPARD
SCHEMBL5498298 0.82 PTPN1 (0.56) PPARGPPARAPTPN1TERTPPARD
SCHEMBL8083757 0.82 PTPN1 (0.56) PPARGPPARAPTPN1TERTPPARD
SCHEMBL15515132 0.80 PTPN1 (0.53) PPARGPPARAPTPN1TERTPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507221-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO Aquinox Pharmaceuticals Inc. (CA) 2012-10-10 EP disclosed
US-8101605-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS INC. (CA) 2012-01-24 US disclosed
WO-2011069118-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 WO disclosed
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO PPM1D, PTPRO, PPM1G PPARG 4471/4885PPARA 3739/4885TSHR 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.